AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma

APMIS

Volumn 118, Issue 2, 2010, Pages 85-90

  Willemoe, Gro Linno ^a   Vainer, Ben ^a  

^a Rigshospitalet   (Denmark)

Author keywords

AMACR; Hepatocellular carcinoma; Immunohistochemical staining; Liver; P504S

Indexed keywords

ALPHA METHYLACYL COANEZYME A RACEMASE; CELL PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RACEMASES AND EPIMERASES;

EID: 75649090099     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02564.x     Document Type: Article

References (26)

1. IARC Globocan 2002 Database. Available from: http://info. cancerresearchuk.org/cancerstats/world/commoncancers (accessed on 26 Nov 2009).
2. Marrero JA, Pelletier S. Hepatocellular carcinoma. Clin Liver Dis 2006 10: 339 351.
3. Hamilton SR, Aaltonen LA. WHO Classification of Tumours: Pathology & Genetics: Tumours of the Digestive System. Lyon: IARC press, 2000.
4. Schmitz W, Albers C, Fingerhut R, Conzelmann E. Purification and characterization of an alfa-methylacyl-CoA racemase from human liver. Eur J Biochem 1995 231: 815 822.
5. Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alfa-Methylacy-CoA racemase-an "obscure" metabolic enzyme takes centre stage. FEBS J 2008 275: 1089 1102.
6. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, et al. Expression of alfa-Methylacyl-CoA Racemase (P504S) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 2003 34: 792 796.
7. Thornburg T, Turner AR, Chen YQ, Vitolins M, Chang B, Xu J. Phytanic acid, AMACR and prostate cancer risk. Future Oncol 2006 2: 213 223. (Pubitemid 43757323)
8. Evans AJ. Alfa-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 2003 56: 892 897.
9. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alfa-Methyl-CoA Racemase: a new molecular marker for prostate cancer. Cancer Res 2002 62: 2220 2226.
10. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA Racemase a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002 26: 926 931.
11. Quaglia A, McStay M, Stoeber K, Loddo M, Caplin M, Fanshawe T, et al. Novel Markers of cell kinetics to evaluate progression from cirrhosis to hepatocellular carcinoma. Liver Int 2006 26: 424 432.
12. Ng IO, Na J, Lai EC, Fan ST, Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol 1995 104: 313 318.
13. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008 32: 433 444.
14. Fischer HP, Flucke U, Zhou H. Pathology along the liver sinusoids: endothelial and perisinusoidal findings. Pathologe 2008 29: 37 46.
15. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006 14: 266 272.
16. Nzeako UC, Goodman ZD, Ishak KG. Comparison of Tumor Pathology with Duration of Survival of North American Patients with Hepatocellular Carcinoma. Cancer 1995 76: 579. 88.
17. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005 22: 88 104.
18. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert opinion. Am J Surg Pathol 2005 29: 874 880.
19. Wang W, Sun X, Epstein JI. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol 2008 32: 851 857.
20. Adley BP, Yang XJ. Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate. Am J Clin Pathol 2006 126: 849 855.
21. Ojanguren I, Ariza A, Castella EM, Ojanguren I, Castellà E, Llatjós M, Ariza A, Navas Palacios JJ. P53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology 1995 26: 63 8.
22. Yusof YA, Yan KL, Hussain SN. Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease. Anal Quant Cytol Histol 2003 25: 332 338.
23. Nonomura A, Ohta G, Hayashi M, et al. Immunohistochemical detection ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am J Gastroentorol 1987 82: 512 518.
24. Cao Y, Merling A, Crocker PR, et al. Differential expression of beta-galactoside alpha2,6-sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest 2002 82: 1515 1524.
25. Guzman G, Wu SJ, Kajdacsy-Balla A, Cotler SJ. Alfa-Methylacyl-CoA Racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes. Appl Immunohistochem Mol Morphol 2006 14: 411 416.
26. Li W, Cagle PT, Botero RC, Liang JJ, Zhang Z, Tan D. Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J Exp Clin Cancer Res 2008 27: 2.